ibudilast has been researched along with Innate Inflammatory Response in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ibudilast-treated participants had lower Cho in superior frontal white matter and nominally lower MI in pregenual anterior cingulate cortex." | 7.11 | Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial. ( Alger, J; Burnette, E; Evans, CJ; Grodin, EN; Irwin, MR; London, ED; Meredith, LR; Miotto, K; Nieto, SJ; O'Neill, J; Ray, LA, 2022) |
| "Ibudilast is a multi-target drug, as it is a phosphodiesterase inhibitor and toll-like receptor 4 (TLR4) antagonist." | 5.91 | Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation. ( Chaudry, O; Figueiredo-Pereira, ME; Liu, Q; Oliveros, G; Qiu, Y; Rockwell, P; Serrano, PA; Wallace, CH; Xie, L, 2023) |
| "Ibudilast-treated participants had lower Cho in superior frontal white matter and nominally lower MI in pregenual anterior cingulate cortex." | 3.11 | Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial. ( Alger, J; Burnette, E; Evans, CJ; Grodin, EN; Irwin, MR; London, ED; Meredith, LR; Miotto, K; Nieto, SJ; O'Neill, J; Ray, LA, 2022) |
| "Ibudilast is a multi-target drug, as it is a phosphodiesterase inhibitor and toll-like receptor 4 (TLR4) antagonist." | 1.91 | Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation. ( Chaudry, O; Figueiredo-Pereira, ME; Liu, Q; Oliveros, G; Qiu, Y; Rockwell, P; Serrano, PA; Wallace, CH; Xie, L, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Oliveros, G | 1 |
| Wallace, CH | 1 |
| Chaudry, O | 1 |
| Liu, Q | 1 |
| Qiu, Y | 1 |
| Xie, L | 1 |
| Rockwell, P | 1 |
| Figueiredo-Pereira, ME | 1 |
| Serrano, PA | 1 |
| Grodin, EN | 1 |
| Nieto, SJ | 1 |
| Meredith, LR | 1 |
| Burnette, E | 1 |
| O'Neill, J | 1 |
| Alger, J | 1 |
| London, ED | 1 |
| Miotto, K | 1 |
| Evans, CJ | 1 |
| Irwin, MR | 1 |
| Ray, LA | 1 |
| Yang, D | 1 |
| Yang, Y | 1 |
| Zhao, Y | 1 |
| Cho, Y | 1 |
| Crichlow, GV | 1 |
| Vermeire, JJ | 1 |
| Leng, L | 1 |
| Du, X | 1 |
| Hodsdon, ME | 1 |
| Bucala, R | 1 |
| Cappello, M | 1 |
| Gross, M | 1 |
| Gaeta, F | 1 |
| Johnson, K | 1 |
| Lolis, EJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)[NCT02714036] | Phase 1/Phase 2 | 35 participants (Actual) | Interventional | 2016-05-06 | Completed | ||
| Phase 1b/2a Single-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of MN-166 (Ibudilast) and Temozolomide Combination Treatment in Patients With Newly Diagnosed or Recurrent Glioblastoma[NCT03782415] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2018-12-29 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ibudilast and Innate Inflammatory Response
| Article | Year |
|---|---|
Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial.
Topics: Alcohol Drinking; Alcoholism; Animals; Aspartic Acid; C-Reactive Protein; Choline; Creatine; Humans; | 2022 |
4 other studies available for ibudilast and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Drug Repositioning; Femal | 2023 |
Ibudilast, a Phosphodiesterase-4 Inhibitor, Ameliorates Acute Respiratory Distress Syndrome in Neonatal Mice by Alleviating Inflammation and Apoptosis.
Topics: Animals; Animals, Newborn; Apoptosis; Bronchoalveolar Lavage Fluid; Cyclic Nucleotide Phosphodiester | 2020 |
Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast.
Topics: Allosteric Site; Binding Sites; Catalysis; Chemotaxis; Crystallography, X-Ray; Cytokines; Humans; In | 2010 |
Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast.
Topics: Allosteric Site; Binding Sites; Catalysis; Chemotaxis; Crystallography, X-Ray; Cytokines; Humans; In | 2010 |
Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast.
Topics: Allosteric Site; Binding Sites; Catalysis; Chemotaxis; Crystallography, X-Ray; Cytokines; Humans; In | 2010 |
Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast.
Topics: Allosteric Site; Binding Sites; Catalysis; Chemotaxis; Crystallography, X-Ray; Cytokines; Humans; In | 2010 |